Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,291 active trials259 approved drugs3,814 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,377 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01548911 | Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Jul 2, 2018 | clinicaltrials |
| NCT03123744 | Histology-Independent Study of Palbociclib in Patients With Advanced Cancer | withdrawn | Phase 2 | 0 | Razelle Kurzrock, MDOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT03149159 |
| Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab |
| withdrawn |
| Phase 2 |
| 0 |
| Medical University of South CarolinaOTHER |
| 1 |
| Jun 18, 2018 |
| clinicaltrials |
| NCT02702960 | Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 15, 2018 | clinicaltrials |
| NCT01134497 | Carboplatin With or Without ZD4054 in Patients With Metastatic Breast Cancer(PLANET) | withdrawn | Phase 2 | 0 | Cardiff UniversityOTHER | 1 | May 22, 2018 | clinicaltrials |
| NCT01162031 | Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT01835288 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 21, 2018 | clinicaltrials |
| NCT00006123 | Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT02985333 | Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02723435 | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | withdrawn | Phase 2 | 0 | Stanford UniversityOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT03282188 | REO13 Melanoma With of Without GM-CSF | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 0 | May 4, 2018 | clinicaltrials |
| NCT03023904 | Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads | withdrawn | Phase 2 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Apr 25, 2018 | clinicaltrials |
| NCT03241017 | Durvalumab in DLBCL After Autologous Transplant(IDA-D) | withdrawn | Phase 2 | 0 | Insel Gruppe AG, University Hospital BernOTHER | 0 | Apr 9, 2018 | clinicaltrials |
| NCT02812693 | Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | withdrawn | Phase 1 / Phase 2 | 0 | Joanne JeterOTHER | 0 | Apr 5, 2018 | clinicaltrials |
| NCT02204020 | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS(UPCI 13-165) | withdrawn | Phase 2 | 0 | University of PittsburghOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT03222089 | Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC | withdrawn | Phase 2 | 0 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 27, 2018 | clinicaltrials |
| NCT03004105 | MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 16, 2018 | clinicaltrials |
| NCT02269579 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | withdrawn | Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01188408 | Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | INSYS Therapeutics IncINDUSTRY | 1 | Mar 12, 2018 | clinicaltrials |
| NCT02962804 | Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC) | withdrawn | Phase 2 | 0 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2018 | clinicaltrials |
| NCT03307603 | Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT02371590 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | withdrawn | Phase 2 | 0 | University of California, San DiegoOTHER | 1 | Feb 23, 2018 | clinicaltrials |
| NCT02856178 | Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients(SAFEGUARD) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT03036046 | Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia(SAFEGUARDFP) | withdrawn | Phase 1 / Phase 2 | 0 | F2G LtdINDUSTRY | 0 | Feb 15, 2018 | clinicaltrials |
| NCT00388700 | A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer | withdrawn | Phase 2 | 0 | Galectin Therapeutics Inc.INDUSTRY | 1 | Feb 14, 2018 | clinicaltrials |
| NCT02845050 | Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)(JaNEO) | withdrawn | Phase 1 / Phase 2 | 0 | Ligartis GmbHINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01788280 | Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003512 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00003534 | Antineoplaston Therapy in Treating Patients With Refractory Stage IV Prostate Cancer | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02720601 | Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers | withdrawn | Phase 2 | 0 | New Mexico Cancer Research AllianceOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT01740570 | Phase I/II Cabazitaxel for Recurrent Malignant Glioma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT01782976 | Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Jan 19, 2018 | clinicaltrials |
| NCT02534181 | Refeeding Syndrome in Cancer Patients(RESCUE) | withdrawn | Phase 2 | 0 | University of Sao PauloOTHER | 0 | Jan 10, 2018 | clinicaltrials |
| NCT02908165 | Randomized Phase II Trial of Chemoembolization and Sorafenib | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT02348255 | NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse | withdrawn | Phase 2 | 0 | University of California, DavisOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT03238638 | A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jan 4, 2018 | clinicaltrials |
| NCT01332617 | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | withdrawn | Phase 2 | 0 | University of LouisvilleOTHER | 0 | Dec 29, 2017 | clinicaltrials |
| NCT02977689 | Trial of IDH305 in IDH1 Mutant Grade II or III Glioma | withdrawn | Phase 2 | 0 | NYU Langone HealthOTHER | 1 | Dec 20, 2017 | clinicaltrials |
| NCT03307941 | Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA(ARTEMIS-Eso) | withdrawn | Phase 1 / Phase 2 | 0 | Jules Bordet InstituteOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02406508 | Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | withdrawn | Phase 2 | 0 | Delcath Systems Inc.INDUSTRY | 1 | Dec 18, 2017 | clinicaltrials |
| NCT00769990 | Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 13, 2017 | clinicaltrials |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT01328106 | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma | withdrawn | Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 0 | Dec 12, 2017 | clinicaltrials |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03130764 | Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Dec 6, 2017 | clinicaltrials |
| NCT00373152 | MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Dec 5, 2017 | clinicaltrials |
| NCT02765997 | StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00855114 | Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01163201 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
| NCT01639456 | CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 2, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Jul 2, 2018source: clinicaltrials